Drugs / SB8
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT02453672 | Apr → Sep 2015 | — | Samsung Bioepis Co., Ltd. | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT02754882 | Jul 2016 → Jan 2018 | non-small cell lung carcinoma | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02453672 ↗ |
| Route | Intravenous | “via intravenous infusion” PMID 32949267 ↗ Sep 2020 |